Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592930 · ClinicalTrials.gov registry record · Phase 4
Olanzapine in the Treatment of Anorexia Nervosa
A Phase 4 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00592930 is a Phase 4 study that has completed, run by Northwell Health. The registered enrollment target is 20 participants.
The verdict
NCT00592930, a Phase 4 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.
Interventions
- DRUG placebo
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2000-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592930
The ClinicalTrials.gov registry entry for NCT00592930 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00592930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592930 about?
NCT00592930 is a clinical study titled "Olanzapine in the Treatment of Anorexia Nervosa". This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.
What is the current status of trial NCT00592930?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2000-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00592930?
The interventions under investigation include: placebo (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT00592930?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.